Cargando…
Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial
BACKGROUND: Despite paucity of data, it is common practice to discontinue metformin before invasive coronary angiography due to an alleged risk of Metformin-Associated Lactic Acidosis (M-ALA). We aimed at assessing the safety of metformin continuation in diabetic patients undergoing coronary angiogr...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902064/ https://www.ncbi.nlm.nih.gov/pubmed/36747244 http://dx.doi.org/10.1186/s12933-023-01744-4 |
_version_ | 1784883165571055616 |
---|---|
author | Chiarito, Mauro Sanz-Sanchez, Jorge Piccolo, Raffaele Condello, Francesco Liccardo, Gaetano Maurina, Matteo Avvedimento, Marisa Regazzoli, Damiano Pagnotta, Paolo Garcia-Garcia, Hector M. Mehran, Roxana Federici, Massimo Condorelli, Gianluigi Diez Gil, Jose Luis Reimers, Bernhard Ferrante, Giuseppe Stefanini, Giulio |
author_facet | Chiarito, Mauro Sanz-Sanchez, Jorge Piccolo, Raffaele Condello, Francesco Liccardo, Gaetano Maurina, Matteo Avvedimento, Marisa Regazzoli, Damiano Pagnotta, Paolo Garcia-Garcia, Hector M. Mehran, Roxana Federici, Massimo Condorelli, Gianluigi Diez Gil, Jose Luis Reimers, Bernhard Ferrante, Giuseppe Stefanini, Giulio |
author_sort | Chiarito, Mauro |
collection | PubMed |
description | BACKGROUND: Despite paucity of data, it is common practice to discontinue metformin before invasive coronary angiography due to an alleged risk of Metformin-Associated Lactic Acidosis (M-ALA). We aimed at assessing the safety of metformin continuation in diabetic patients undergoing coronary angiography in terms of significant increase in lactate levels. METHODS: In this open-label, prospective, multicentre, single-arm trial, all diabetic patients undergoing coronary angiography with or without percutaneous coronary intervention at 3 European centers were screened for enrolment. The primary endpoint was the increase in lactate levels from preprocedural levels at 72-h after the procedure. Secondary endpoints included contrast associated-acute kidney injury (CA-AKI), M-ALA, and all-cause mortality. RESULTS: 142 diabetic patients on metformin therapy were included. Median preprocedural lactate level was 1.8 mmol/l [interquartile range (IQR) 1.3–2.3]. Lactate levels at 72 h after coronary angiography were 1.7 mmol/l (IQR 1.3–2.3), with no significant differences as compared to preprocedural levels (p = 0.91; median difference = 0; IQR − 0.5 to 0.4 mmol/l). One patient had 72-h levels ≥ 5 mmol/l (5.3 mmol/l), but no cases of M-ALA were reported. CA-AKI occurred in 9 patients (6.1%) and median serum creatinine and estimated glomerular filtration rate remained similar throughout the periprocedural period. At a median follow-up of 90 days (43–150), no patients required hemodialysis and 2 patients died due to non-cardiac causes. CONCLUSIONS: In diabetic patients undergoing invasive coronary angiography, metformin continuation throughout the periprocedural period does not increase lactate levels and was not associated with any decline in renal function. Trial registration: The study was registered at Clinicaltrials.gov (NCT04766008). GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-023-01744-4. |
format | Online Article Text |
id | pubmed-9902064 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99020642023-02-07 Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial Chiarito, Mauro Sanz-Sanchez, Jorge Piccolo, Raffaele Condello, Francesco Liccardo, Gaetano Maurina, Matteo Avvedimento, Marisa Regazzoli, Damiano Pagnotta, Paolo Garcia-Garcia, Hector M. Mehran, Roxana Federici, Massimo Condorelli, Gianluigi Diez Gil, Jose Luis Reimers, Bernhard Ferrante, Giuseppe Stefanini, Giulio Cardiovasc Diabetol Research BACKGROUND: Despite paucity of data, it is common practice to discontinue metformin before invasive coronary angiography due to an alleged risk of Metformin-Associated Lactic Acidosis (M-ALA). We aimed at assessing the safety of metformin continuation in diabetic patients undergoing coronary angiography in terms of significant increase in lactate levels. METHODS: In this open-label, prospective, multicentre, single-arm trial, all diabetic patients undergoing coronary angiography with or without percutaneous coronary intervention at 3 European centers were screened for enrolment. The primary endpoint was the increase in lactate levels from preprocedural levels at 72-h after the procedure. Secondary endpoints included contrast associated-acute kidney injury (CA-AKI), M-ALA, and all-cause mortality. RESULTS: 142 diabetic patients on metformin therapy were included. Median preprocedural lactate level was 1.8 mmol/l [interquartile range (IQR) 1.3–2.3]. Lactate levels at 72 h after coronary angiography were 1.7 mmol/l (IQR 1.3–2.3), with no significant differences as compared to preprocedural levels (p = 0.91; median difference = 0; IQR − 0.5 to 0.4 mmol/l). One patient had 72-h levels ≥ 5 mmol/l (5.3 mmol/l), but no cases of M-ALA were reported. CA-AKI occurred in 9 patients (6.1%) and median serum creatinine and estimated glomerular filtration rate remained similar throughout the periprocedural period. At a median follow-up of 90 days (43–150), no patients required hemodialysis and 2 patients died due to non-cardiac causes. CONCLUSIONS: In diabetic patients undergoing invasive coronary angiography, metformin continuation throughout the periprocedural period does not increase lactate levels and was not associated with any decline in renal function. Trial registration: The study was registered at Clinicaltrials.gov (NCT04766008). GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-023-01744-4. BioMed Central 2023-02-06 /pmc/articles/PMC9902064/ /pubmed/36747244 http://dx.doi.org/10.1186/s12933-023-01744-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Chiarito, Mauro Sanz-Sanchez, Jorge Piccolo, Raffaele Condello, Francesco Liccardo, Gaetano Maurina, Matteo Avvedimento, Marisa Regazzoli, Damiano Pagnotta, Paolo Garcia-Garcia, Hector M. Mehran, Roxana Federici, Massimo Condorelli, Gianluigi Diez Gil, Jose Luis Reimers, Bernhard Ferrante, Giuseppe Stefanini, Giulio Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial |
title | Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial |
title_full | Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial |
title_fullStr | Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial |
title_full_unstemmed | Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial |
title_short | Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial |
title_sort | safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the no-stop single arm trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902064/ https://www.ncbi.nlm.nih.gov/pubmed/36747244 http://dx.doi.org/10.1186/s12933-023-01744-4 |
work_keys_str_mv | AT chiaritomauro safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial AT sanzsanchezjorge safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial AT piccoloraffaele safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial AT condellofrancesco safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial AT liccardogaetano safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial AT maurinamatteo safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial AT avvedimentomarisa safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial AT regazzolidamiano safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial AT pagnottapaolo safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial AT garciagarciahectorm safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial AT mehranroxana safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial AT federicimassimo safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial AT condorelligianluigi safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial AT diezgiljoseluis safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial AT reimersbernhard safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial AT ferrantegiuseppe safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial AT stefaninigiulio safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial |